
An Unexpected Chromophobe RCC Diagnosis
February 6, 2025
This is a guest post by Rachele Funes, 35. She and her family live in Florida. It was a week…
Read MoreAttendees at the inaugural Advanced Urologic Cancer Consensus Conference (AUC3) met in Miami, Florida on January 23-24 to agree on optimal diagnostic and management strategies for kidney and bladder cancers.
“Tremendous progress has been made in the treatment of patients with advanced urologic cancers, but experts believe critical questions remain that are unable to be answered by robust prospective clinical trials. AUC3 aims to address this scarcity of information,” wrote organizers of the meeting, which included the conference organizers.
“KCA’s Board & Medical Steering Committee members participated in AUC3 to align on optimal diagnostic & management strategies for kidney & bladder cancer — working together to advance patient care,” said Gretchen E. Vaughan, KCA’s President and CEO. “By fostering collaboration among top experts, we help ensure the latest advancements reach all patients, especially those without access to leading specialists. This work is critical in propelling KCA’s mission to improve cancer care for everyone.”
Presenters and panelists helmed debates related to kidney cancer including topics such as adjuvant (pre-surgery) immunotherapy, additional rounds of immunotherapy even when a patients’ disease progresses, and genetic testing:
“Building consensus and guidance for the RCC field like this will save lives and advance research,” said Dr. Stephanie Berg, a medical oncologist at the Dana-Farber Cancer Institute. “Advocacy organizations like the Kidney Cancer Association can support patients and providers by helping to explain potential new guidance and how they reflect consensus from the top researchers and clinical providers in genitourinary oncology from around the world.”